| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K16130065 | CTRPv2 | pan-cancer | AAC | 0.0054 | 0.9 |
| mRNA | pac-1 | CTRPv2 | pan-cancer | AAC | 0.0026 | 0.9 |
| mRNA | C6-ceramide | CTRPv2 | pan-cancer | AAC | -0.0027 | 0.9 |
| mRNA | HBX-41108 | CTRPv2 | pan-cancer | AAC | 0.0028 | 0.9 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0024 | 0.9 |
| mRNA | tipifarnib | CTRPv2 | pan-cancer | AAC | 0.002 | 0.9 |
| mRNA | Erlotinib | CTRPv2 | pan-cancer | AAC | 0.0022 | 0.9 |
| mRNA | Merck60 | CTRPv2 | pan-cancer | AAC | -0.0018 | 0.9 |
| mRNA | BRD-K61166597 | CTRPv2 | pan-cancer | AAC | -0.0019 | 1 |
| mRNA | BRD-K55473186 | CTRPv2 | pan-cancer | AAC | -0.0024 | 1 |